Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase I/II Open-label and Single-arm and Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Protocol ID
CINC424F12201 / REACH4
Disease (Sub Disease)
Acute Graft Versus Host Disease
Diagnosis Stage
New Diagnosis
Relapse/Refractory
Relapse/Refractory
Sponsor
Novartis Pharmaceuticals
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 17 years
International registry ID's
NCT03491215
| Study Title | A Phase I/II Open-label and Single-arm and Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation |
|---|---|
| Protocol ID | CINC424F12201 / REACH4 |
| Disease (Sub Disease) | Acute Graft Versus Host Disease |
| Diagnosis Stage | New Diagnosis Relapse/Refractory |
| Sponsor | Novartis Pharmaceuticals |
| Links | https://clinicaltrials.gov/ct2/show/NCT03491215 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 23/08/2018 |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | up to 17 years |
| International registry ID's | NCT03491215 |